IL131274A0 - Estrogen agonists/antagonists - Google Patents
Estrogen agonists/antagonistsInfo
- Publication number
- IL131274A0 IL131274A0 IL13127499A IL13127499A IL131274A0 IL 131274 A0 IL131274 A0 IL 131274A0 IL 13127499 A IL13127499 A IL 13127499A IL 13127499 A IL13127499 A IL 13127499A IL 131274 A0 IL131274 A0 IL 131274A0
- Authority
- IL
- Israel
- Prior art keywords
- antagonists
- estrogen agonists
- estrogen
- agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9552298P | 1998-08-06 | 1998-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL131274A0 true IL131274A0 (en) | 2001-01-28 |
Family
ID=22252388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13127499A IL131274A0 (en) | 1998-08-06 | 1999-08-05 | Estrogen agonists/antagonists |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1004306A3 (de) |
| JP (1) | JP2000080038A (de) |
| KR (1) | KR20000017101A (de) |
| AR (1) | AR021747A1 (de) |
| AU (1) | AU4341099A (de) |
| CA (1) | CA2279747A1 (de) |
| HU (1) | HUP9902674A2 (de) |
| IL (1) | IL131274A0 (de) |
| PE (1) | PE20001003A1 (de) |
| ZA (1) | ZA995029B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| CN1679956A (zh) * | 2001-11-29 | 2005-10-12 | Gtx公司 | 治疗因雄激素剥夺引起的症状 |
| US20040248989A1 (en) * | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US6391892B1 (en) * | 1995-03-10 | 2002-05-21 | Eli Lilly And Company | Naphthyl pharmaceutical compounds |
| JPH1025263A (ja) * | 1996-02-13 | 1998-01-27 | Sankyo Co Ltd | フラバノン及びそのカルバ誘導体 |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
| CA2215647A1 (en) * | 1996-10-24 | 1998-04-24 | Eli Lilly And Company | Naphthyl compounds, compositions, and methods |
| EP0950417A3 (de) * | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Behandlung von Skeletterkrankungen |
| CA2335112A1 (en) * | 1998-06-16 | 1999-12-23 | Hua Zhu Ke | Therapeutic combinations for musculoskeletal frailty |
-
1999
- 1999-07-28 EP EP99305982A patent/EP1004306A3/de not_active Withdrawn
- 1999-08-04 PE PE1999000785A patent/PE20001003A1/es not_active Application Discontinuation
- 1999-08-04 AR ARP990103877A patent/AR021747A1/es unknown
- 1999-08-04 CA CA002279747A patent/CA2279747A1/en not_active Abandoned
- 1999-08-05 KR KR1019990032094A patent/KR20000017101A/ko not_active Ceased
- 1999-08-05 AU AU43410/99A patent/AU4341099A/en not_active Abandoned
- 1999-08-05 HU HU9902674A patent/HUP9902674A2/hu unknown
- 1999-08-05 IL IL13127499A patent/IL131274A0/xx unknown
- 1999-08-05 ZA ZA9905029A patent/ZA995029B/xx unknown
- 1999-08-06 JP JP11224000A patent/JP2000080038A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU4341099A (en) | 2000-03-02 |
| CA2279747A1 (en) | 2000-02-06 |
| EP1004306A2 (de) | 2000-05-31 |
| AR021747A1 (es) | 2002-08-07 |
| KR20000017101A (ko) | 2000-03-25 |
| PE20001003A1 (es) | 2000-10-11 |
| EP1004306A3 (de) | 2000-06-07 |
| ZA995029B (en) | 2001-02-05 |
| JP2000080038A (ja) | 2000-03-21 |
| HU9902674D0 (en) | 1999-10-28 |
| HUP9902674A2 (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG23913A (en) | Estrogen agonists / antagonists | |
| AP2000001916A0 (en) | 2-Adrenergic receptor agonists | |
| AU1772300A (en) | Glucagon antagonists/inverse agonists | |
| GB2346760B (en) | Earphone-microphone adapter | |
| GB9808475D0 (en) | An Adapter | |
| GB9804426D0 (en) | Heterocycles | |
| PL346247A1 (en) | Muscarinic agonists and antagonists | |
| GB9826359D0 (en) | Novel receptors | |
| IL140249A0 (en) | Muscarinic antagonists | |
| AUPP380498A0 (en) | Egf receptor agonists and antagonists | |
| GB9805486D0 (en) | Adapter | |
| GB9807075D0 (en) | Endometrial samplers | |
| AU4961499A (en) | 5-HT1f agonists | |
| GB2342863B (en) | Probe | |
| GB9810354D0 (en) | Heterocycles | |
| GB2340521B (en) | Shale-stabilizing additives | |
| HUP0004317A3 (en) | 5-ht1f agonists | |
| GB9803425D0 (en) | Microtome | |
| EP1084142A4 (de) | Gpr35a-rezeptor | |
| IL144355A0 (en) | 5-ht1f agonists | |
| HU0002979D0 (en) | Estrogen agonists and antagonists for multiple indications | |
| IL131274A0 (en) | Estrogen agonists/antagonists | |
| EP1083909A4 (de) | hCEPR REZEPTOR | |
| EP1109565A4 (de) | Gabab1aa rezeptor | |
| GB9811283D0 (en) | Vironectin receptor antagonists |